Cargando…
Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome
A 3.5 year old Hispanic female presented with signs and symptoms concerning for MPS II (Hunter Syndrome). The diagnosis of MPS II was confirmed by enzyme and molecular testing. Genetic evaluation revealed undetectable plasma iduronate-2-sulfatase enzyme activity and an inversion between intron 7 of...
Autores principales: | Julien, Daniel C., Woolgar, Kara, Pollard, Laura, Miller, Holly, Desai, Ankit, Lindstrom, Kristin, Kishnani, Priya S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253587/ https://www.ncbi.nlm.nih.gov/pubmed/32508845 http://dx.doi.org/10.3389/fimmu.2020.01000 |
Ejemplares similares
-
Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy
por: Desai, Ankit K., et al.
Publicado: (2019) -
Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
por: Desai, Ankit K., et al.
Publicado: (2020) -
A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation
por: Curelaru, Shiri, et al.
Publicado: (2022) -
Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease
por: De Groot, Anne S., et al.
Publicado: (2021) -
Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy
por: Kim, Katherine H., et al.
Publicado: (2023)